Company news

Apellis Pharmaceuticals, Inc. news in 2025

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

December 12, 2025

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

December 2, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

November 24, 2025

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

November 11, 2025

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

November 4, 2025

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

October 29, 2025

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

October 19, 2025

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

October 15, 2025

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

July 30, 2025

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

July 27, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

July 23, 2025

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

June 30, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

June 5, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

May 5, 2025

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

April 29, 2025

Apellis Announces Craig Wheeler to Join the Board of Directors

April 20, 2025

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

March 31, 2025

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

February 23, 2025

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

February 19, 2025

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

February 13, 2025

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 3, 2025

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

January 26, 2025

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

Apellis Announces Keli Walbert to Join the Board of Directors

January 9, 2025

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025